Found 28 clinical trials
A Phase II Trial of Pembrolizumab Plus Olaparib for the Treatment of Patients With Persistent/Recurrent Endometrial Cancers
carcinosarcoma. The researchers will also look at the safety of the drug combination and whether it causes few or mild side effects in participants.
- 0 views
- 13 Oct, 2022
- 3 locations
Pazopanib vs. Pazopanib Plus Gemcitabine (PazoDoble)
This study is a prospective, randomized, open-label, multicenter phase II trial in order to determine progression-free survival of patients with refractory or relapsed metastatic uterine leiomyosarcomas or other metastatic uterine tumours.
- 2 views
- 12 Feb, 2022
- 4 locations
ATr Inhibitor in Combination With Olaparib in Gynaecological Cancers With ARId1A Loss or no Loss (ATARI)
ATARI trial tests the ATR inhibitor drug AZD6738 and a PARP inhibitor drug olaparib in patients with relapsed gynecological cancers to assess the response in groups of patients selected based on their cancer cell subtype and the presence of an abnormality in ARID1A gene.
- 6 views
- 19 Feb, 2022
- 1 location
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-Oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
(paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted
- 0 views
- 21 Oct, 2022
- 21 locations
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
carcinoma (temporarily closed to accrual 04/29/2020) Clear cell cervical cancer Esthenioneuroblastoma (closed to accrual) Endometrial carcinosarcoma (malignant mixed Mullerian
- 6651 views
- 22 Oct, 2022
- 752 locations
Sentinel Lymph Node Sampling for Patients With Middle-high Risk Endometrial Cancer Confined to the Uterus
Aim To investigate the effect of sentinel lymph node (SLN) sampling on the prognosis of patients with middle-high risk endometrial cancer obviously confined to the uterus before surgery.
- 0 views
- 09 Apr, 2022
- 1 location
Nivolumab for Recurrent/Metastatic Carcinosarcoma
Carcinosarcoma is a malignant neoplasm that is composed of both epithelial and mesenchymal elements and aggressive tumor that are staged as high-grade cancer in NCCN guideline. They are regarded
- 0 views
- 26 Mar, 2022
- 1 location
Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib (ROCSAN)
Carcinosarcomas (CS) (malignant mixed Müllerian tumors) are highly aggressive and rare tumors with a worldwide annual incidence between 0.5-3.3 cases/100.000 women. Gynecological CS, i.e. ovarian CS (OCS) and uterine CS (UCS), have a 5-year overall survival (OS) < 10% and a poor prognosis. After initial treatment (surgery +/- adjuvant radiotherapies …
- 1 views
- 14 Mar, 2022
- 16 locations
A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma
The purpose of this study to find out whether the combination of lenvatinib and pembrolizumab is an effective treatment for advanced uterine carcinosarcoma. The researchers will also do tests to
- 0 views
- 12 May, 2022
- 7 locations
Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma
This study is to explore the treatment of advanced sarcomatoid carcinoma or Carcinosarcoma with Carrelizumab combined with Apatinib, in order to provide guidance and experience for new combined
- 0 views
- 06 Mar, 2022
- 1 location